Caliper Debuts LabChip For Drug Discovery; Waits On Molecular Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
The appointment of Daniel Kisner, PhD, as chief executive officer of Caliper Technologies reflects the company's intention to keep its LabChip technology focused on pharmaceutical applications while long-term development in diagnostics continues.
You may also be interested in...
Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D
Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.